Saliva as a window into tumor immunity in oral squamous cell carcinoma: tissue concordance and translational validation
- 1Department of Oral Medicine, Stomatological Hospital, Southern Medical University
- 2Department of Periodontology and Oral Implantology, Stomatological Hospital, Southern Medical University
Abstract
Saliva is non-invasive, repeatable, and anatomically close to oral squamous cell carcinoma (OSCC), but proximity does not establish that a salivary biomolecule originates from the tumor. Cytokines, extracellular vesicles, coding and non-coding RNAs, and tumor-derived DNA may arise from tumor and immune cells, adjacent mucosa, periodontal tissues, salivary glands, oral microbiota, or systemic circulation. This review evaluates whether salivary immune signals reflect the OSCC tissue immune microenvironment using three evidence levels: quantitative paired tissue-saliva concordance within patients (Level I); indirect clinicopathological, source-enriched, paired-biofluid, or longitudinal support without quantitative paired tissue analysis (Level II); and saliva-only case-control differences (Level III). IL-6, IL-8/CXCL8, IL-1β, and TNF-α show relatively consistent salivary changes, whereas evidence for IL-10, selected chemokines, extracellular vesicle-associated PD-L1, and secreted miRNAs or lncRNAs remains limited or inconsistent. Salivary tumor DNA can show strong tissue-genotype concordance, but reflects tumor-derived material rather than immune state. Most immune candidates remain at Level II or III; none robustly meets Level I. Periodontitis, mucositis, infection, smoking, tumor ulceration, salivary flow, and sample processing complicate interpretation. We propose paired collection of tumor, adjacent mucosa, saliva, and plasma; spatial immunophenotyping; oral-inflammation controls; longitudinal perioperative and treatment sampling; standardized assays; and multicenter validation. The framework prioritizes biological traceability over diagnostic discrimination. At present, saliva is best considered a complementary longitudinal biosample, not a substitute for tissue immunophenotyping.
Related
- Transcriptomic Profiling Reveals METTL26 as a Potential Biomarker in Head and Neck Squamous Cell Carcinoma with Independent Validation in Oral Squamous Cell Carcinoma
- Longitudinal liquid biopsy alongside positron emission tomography‐computed tomography surveillance in p16‐positive oropharyngeal squamous cell carcinoma: A translational case study
- Pan-Cancer Landscape of TMEM9 With Experimental Validation in Head and Neck Squamous Cell Carcinoma.
- Misreporting of study design and validation status in a study of early tumour shrinkage in esophageal squamous cell carcinoma
- Development and Patient-Level Internal Validation of an MRI-Based Radiomics Machine Learning Model for Preoperative Prediction of Cervical Lymph Node Metastasis in Oral Squamous Cell Carcinoma: A Pilot Study.
BibTeX
@article{hu2026saliva,
title = {{Saliva as a window into tumor immunity in oral squamous cell carcinoma: tissue concordance and translational validation}},
author = {Huiting Hu and Yong Yang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1957454},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1957454/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Saliva as a window into tumor immunity in oral squamous cell carcinoma: tissue concordance and translational validation
AU - Huiting Hu
AU - Yong Yang
PY - 2026
DA - 2026/10/08
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1957454
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1957454/full
AB - Saliva is non-invasive, repeatable, and anatomically close to oral squamous cell carcinoma (OSCC), but proximity does not establish that a salivary biomolecule originates from the tumor. Cytokines, extracellular vesicles, coding and non-coding RNAs, and tumor-derived DNA may arise from tumor and immune cells, adjacent mucosa, periodontal tissues, salivary glands, oral microbiota, or systemic circulation. This review evaluates whether salivary immune signals reflect the OSCC tissue immune microenvironment using three evidence levels: quantitative paired tissue-saliva concordance within patients (Level I); indirect clinicopathological, source-enriched, paired-biofluid, or longitudinal support without quantitative paired tissue analysis (Level II); and saliva-only case-control differences (Level III). IL-6, IL-8/CXCL8, IL-1β, and TNF-α show relatively consistent salivary changes, whereas evidence for IL-10, selected chemokines, extracellular vesicle-associated PD-L1, and secreted miRNAs or lncRNAs remains limited or inconsistent. Salivary tumor DNA can show strong tissue-genotype concordance, but reflects tumor-derived material rather than immune state. Most immune candidates remain at Level II or III; none robustly meets Level I. Periodontitis, mucositis, infection, smoking, tumor ulceration, salivary flow, and sample processing complicate interpretation. We propose paired collection of tumor, adjacent mucosa, saliva, and plasma; spatial immunophenotyping; oral-inflammation controls; longitudinal perioperative and treatment sampling; standardized assays; and multicenter validation. The framework prioritizes biological traceability over diagnostic discrimination. At present, saliva is best considered a complementary longitudinal biosample, not a substitute for tissue immunophenotyping.
SN - 1664-3224
ER -